(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 189.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Nuvation Bio's revenue in 2025 is $10,957,000.On average, 3 Wall Street analysts forecast NUVB's revenue for 2025 to be $8,140,111,175, with the lowest NUVB revenue forecast at $5,716,417,997, and the highest NUVB revenue forecast at $11,524,706,997. On average, 3 Wall Street analysts forecast NUVB's revenue for 2026 to be $42,910,563,903, with the lowest NUVB revenue forecast at $29,228,589,638, and the highest NUVB revenue forecast at $51,512,411,937.
In 2027, NUVB is forecast to generate $97,614,642,555 in revenue, with the lowest revenue forecast at $97,614,642,555 and the highest revenue forecast at $97,614,642,555.